Comparing MindWalk (HYFT) and Its Peers

MindWalk (NASDAQ:HYFT) is one of 458 publicly-traded companies in the “Pharmaceutical Preparations” industry, but how does it weigh in compared to its rivals? We will compare MindWalk to similar companies based on the strength of its analyst recommendations, dividends, valuation, risk, earnings, profitability and institutional ownership.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for MindWalk and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MindWalk	1	1	0	0	1.50
MindWalk Competitors	4898	9969	15994	377	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 65.25%. Given MindWalk’s rivals stronger consensus rating and higher probable upside, analysts clearly believe MindWalk has less favorable growth aspects than its rivals.

Earnings and Valuation

This table compares MindWalk and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
MindWalk	$17.59 million	-$21.69 million	-1.88
MindWalk Competitors	$432.12 million	-$67.78 million	-10.61

MindWalk’s rivals have higher revenue, but lower earnings than MindWalk. MindWalk is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

6.7% of MindWalk shares are owned by institutional investors. Comparatively, 39.1% of shares of all “Pharmaceutical Preparations” companies are owned by institutional investors. 6.8% of MindWalk shares are owned by company insiders. Comparatively, 13.9% of shares of all “Pharmaceutical Preparations” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares MindWalk and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MindWalk	-145.58%	-56.75%	-31.55%
MindWalk Competitors	-2,662.14%	-363.93%	-42.95%

Risk & Volatility

MindWalk has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500. Comparatively, MindWalk’s rivals have a beta of 5.62, indicating that their average share price is 462% more volatile than the S&P 500.

Summary

MindWalk rivals beat MindWalk on 8 of the 13 factors compared.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.